Real-Time Motion Analysis Reveals Cell Directionality as an Indicator of Breast Cancer Progression

Cancer cells alter their migratory properties during tumor progression to invade surrounding tissues and metastasize to distant sites. However, it remains unclear how migratory behaviors differ between tumor cells of different malignancy and whether these migratory behaviors can be utilized to assess the malignant potential of tumor cells. Here, we analyzed the migratory behaviors of cell lines representing different stages of breast cancer progression using conventional migration assays or time-lapse imaging and particle image velocimetry (PIV) to capture migration dynamics. We find that the number of migrating cells in transwell assays, and the distance and speed of migration in unconstrained 2D assays, show no correlation with malignant potential. However, the directionality of cell motion during 2D migration nicely distinguishes benign and tumorigenic cell lines, with tumorigenic cell lines harboring less directed, more random motion. Furthermore, the migratory behaviors of epithelial sheets observed under basal conditions and in response to stimulation with epidermal growth factor (EGF) or lysophosphatitic acid (LPA) are distinct for each cell line with regard to cell speed, directionality, and spatiotemporal motion patterns. Surprisingly, treatment with LPA promotes a more cohesive, directional sheet movement in lung colony forming MCF10CA1a cells compared to basal conditions or EGF stimulation, implying that the LPA signaling pathway may alter the invasive potential of MCF10CA1a cells. Together, our findings identify cell directionality as a promising indicator for assessing the tumorigenic potential of breast cancer cell lines and show that LPA induces more cohesive motility in a subset of metastatic breast cancer cells.

[1]  P Rosen,et al.  Cell density determines epithelial migration in culture. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Jose Russo,et al.  Human Breast Epithelial Cell Line, MCF-10 Isolation and Characterization of a Spontaneously Immortalized , 2006 .

[3]  P. Friedl,et al.  Migration of coordinated cell clusters in mesenchymal and epithelial cancer explants in vitro. , 1995, Cancer research.

[4]  Stephen Pulman,et al.  Building the Framework , 1996 .

[5]  F. Miller,et al.  MCF10AT: a model for the evolution of cancer from proliferative breast disease. , 1996, The American journal of pathology.

[6]  T. Beckers,et al.  Overexpression of EGFR and c‐erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts , 1998, FEBS letters.

[7]  D. Stern Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases , 2000, Breast Cancer Research.

[8]  A. Ramaioli,et al.  Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Alan Wells,et al.  Growth Factor-Induced Cell Motility in Tumor Invasion , 2002, Acta oncologica.

[10]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[11]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[12]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[13]  D. Im,et al.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. , 2003, Molecular pharmacology.

[14]  L. Wakefield,et al.  The two faces of transforming growth factor beta in carcinogenesis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Donna J. Webb,et al.  New dimensions in cell migration , 2003, Nature Cell Biology.

[17]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[18]  C. J. Barnes,et al.  Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets , 2003, Cancer and Metastasis Reviews.

[19]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[20]  P. Clézardin,et al.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. , 2004, The Journal of clinical investigation.

[21]  C. J. Barnes,et al.  The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells , 2004, Clinical Cancer Research.

[22]  Erik Sahai,et al.  Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. , 2005, Cancer research.

[23]  J. Pfeilschifter,et al.  The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. , 2005, Biochimica et biophysica acta.

[24]  Timothy J Mitchison,et al.  Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. , 2005, Chemistry & biology.

[25]  S. Steinberg,et al.  Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. , 2005, Journal of the National Cancer Institute.

[26]  J. McCubrey,et al.  EGF Induces Cell Motility and Multi-Drug Resistance Gene Expression in Breast Cancer Cells , 2006, Cell cycle.

[27]  P. Clézardin,et al.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Stanislav Y Shvartsman,et al.  Role of boundary conditions in an experimental model of epithelial wound healing. , 2006, American journal of physiology. Cell physiology.

[29]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[30]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[31]  Jeffrey Wyckoff,et al.  Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. , 2006, Cancer research.

[32]  E. Sahai,et al.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells , 2007, Nature Cell Biology.

[33]  P. Chavrier,et al.  Collective migration of an epithelial monolayer in response to a model wound , 2007, Proceedings of the National Academy of Sciences.

[34]  Min Chen,et al.  LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. , 2007, American journal of physiology. Cell physiology.

[35]  Alan Wells,et al.  EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation , 2007, Journal of Cell Science.

[36]  Anastasia Khvorova,et al.  Identification of genes that regulate epithelial cell migration using an siRNA screening approach , 2008, Nature Cell Biology.

[37]  D. Lauffenburger,et al.  A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. , 2008, Developmental cell.

[38]  N. Marella,et al.  Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. , 2009, Cancer research.

[39]  Yiling Lu,et al.  Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. , 2009, Cancer cell.

[40]  James I. Fells,et al.  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. , 2009, Cancer research.

[41]  G. Mills,et al.  β-Arrestin/Ral Signaling Regulates Lysophosphatidic Acid–Mediated Migration and Invasion of Human Breast Tumor Cells , 2009, Molecular Cancer Research.

[42]  Erik Sahai,et al.  Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.

[43]  P. Friedl,et al.  Collective cell migration in morphogenesis, regeneration and cancer , 2009, Nature Reviews Molecular Cell Biology.

[44]  I. Takeyoshi,et al.  LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. , 2009, Carcinogenesis.

[45]  P. Friedl,et al.  The Journal of Cell Biology , 2002 .

[46]  M. Poujade,et al.  Velocity fields in a collectively migrating epithelium. , 2010, Biophysical journal.

[47]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[48]  Mitsutaka Kadota,et al.  Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines , 2010, PloS one.

[49]  S. Lipkowitz,et al.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. , 2010, Breast disease.

[50]  Jun Du,et al.  Lysophosphatidic Acid Induces MDA-MB-231 Breast Cancer Cells Migration through Activation of PI3K/PAK1/ERK Signaling , 2010, PloS one.

[51]  Graeme I Murray,et al.  Current and emerging concepts in tumour metastasis , 2010, The Journal of pathology.

[52]  Akira Oshima,et al.  Transient Tumor-Fibroblast Interactions Increase Tumor Cell Malignancy by a TGF-β Mediated Mechanism in a Mouse Xenograft Model of Breast Cancer , 2010, PloS one.

[53]  G. Mills,et al.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression , 2010, British Journal of Cancer.

[54]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[55]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[56]  J Downward,et al.  An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis , 2011, Oncogene.

[57]  King-Jen Chang,et al.  Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis , 2011, PloS one.

[58]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[59]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[60]  R. Gomis,et al.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. , 2012, The Journal of clinical investigation.

[61]  Alan Wells,et al.  2D protrusion but not motility predicts growth factor–induced cancer cell migration in 3D collagen , 2012, The Journal of cell biology.

[62]  J. Käs,et al.  Directed persistent motion maintains sheet integrity during multi-cellular spreading and migration , 2012 .

[63]  O. Kallioniemi,et al.  Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models , 2011, Oncogene.

[64]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[65]  A. Sigal,et al.  Collective and single cell behavior in epithelial contact inhibition , 2011, Proceedings of the National Academy of Sciences.

[66]  C. Sotiriou,et al.  Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions , 2012, Oncogene.

[67]  Stephen T C Wong,et al.  Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis , 2012, Cancer.

[68]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[69]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .